SGMO - Sangamo Therapeutics EPS misses by $0.02 beats on revenue

Sangamo Therapeutics (SGMO): Q1 GAAP EPS of -$0.32 misses by $0.02.Revenue of $26.28M (+100.9% Y/Y) beats by $2.08M.Guidance for 2021 Reiterated (initial guidance provided on February 24, 2021).On a GAAP basis, we expect total operating expenses, including non-cash stock-based compensation expenses, to be in the range of approximately $285 million to $305 million.On a non-GAAP basis, we expect total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $30 million, to be in the range of approximately $255 million to $275 million.Press Release

For further details see:

Sangamo Therapeutics EPS misses by $0.02, beats on revenue